IONIS PHARMACEUTICALS INC (IONS)
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core segment. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia on January 10, 1989 and is headquartered in Carlsbad, CA.
Address
2855 GAZELLE COURT
CARLSBAD, CA 92010
Founded
1989
Number of Employees
927
Website
http://www.ionis.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s ) |
- | - | - | - | - | $34 | $91 | - | - | - | - | $62 |
| Average Price | - | - | - | - | - | $64.28 | $61.27 | - | - | - | - | $62.07 |
| # Shares Purchased | - | - | - | - | - | 535 | 1,478 | - | - | - | - | 1,007 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | -34.7% | -31.5% | - | - | - | - | -32.3% |
| S&P 500 Return to Date | - | - | - | - | - | 93.1% | 74.8% | - | - | - | - | 84.0% |
| Excess Total Return | - | - | - | - | - | -127.8% | -106.3% | - | - | - | - | -116.3% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | 17% | 14% | - | - | - | - | 22% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at IONS make a trade.
Creating a free account takes less than one minute